Choosing the optimal nonstatin lipid lowering therapies for statin-intolerant patients: A systematic review and network meta-analysis
Authors:
- Wattakorn LaohapiboolrattanaWLWattakorn Laohapiboolrattana
- Paisit KosumPKPaisit Kosum
- Kansak BoonpattharatthitiKBKansak Boonpattharatthiti
- Nonthikorn TheerasuwipakornNTNonthikorn Theerasuwipakorn
- Duangnapa RoongpiboonsopitDRDuangnapa Roongpiboonsopit
- Pattamawan KosumaPKPattamawan Kosuma
- Teerapon DhippayomTDTeerapon Dhippayom
- 5 August 2025
- journal article
- review article
- Published by Elsevier in Journal of Clinical Lipidology
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Statin Intolerance: an Overview of US and International GuidanceCurrent Atherosclerosis Reports, 2023
- NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patientJournal of Clinical Lipidology, 2022
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled studyAtherosclerosis, 2018
- Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) TrialClinical Cardiology, 2016
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialJournal of Clinical Lipidology, 2015
- A systematic review of statin-induced muscle problems in clinical trialsAmerican Heart Journal, 2014
- Anti-PCSK9 Monotherapy for HypercholesterolemiaJACC, 2014
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin IntoleranceJACC, 2014
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 2005